Table 3. Crude and Adjusted HRs of Patients With Lung Cancer Treated With Different TKIs, Including Erlotinib, Gefitinib, and Afatinib.
| Variable | Patients, No. (%) | Crude HR (95% CI) | P value | Adjusted HR (95% CI)a | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Total (n = 12 666) | Gefitinib use (n = 4222) [Reference] | Erlotinib use (n = 4222) | Afatinib use (n = 4222) | ||||||
| All cause death | 8744 (69.04) | 2916 (69.07) | 3065 (72.60) | 2763 (65.44) | Erlotinib | 1.12 (1.07-1.18) | <.001 | 1.12 (1.07-1.18) | <.001 |
| Afatinib | 0.86 (0.82-0.91) | <.001 | 0.90 (0.85-0.94) | <.001 | |||||
| MACCEs | 1524 (12.03) | 552 (13.07) | 502 (11.80) | 470 (11.13) | Erlotinib | 0.96 (0.85-1.08) | .46 | 1.03 (0.91-1.16) | .68 |
| Afatinib | 0.78 (0.69-0.88) | <.001 | 0.97 (0.85-1.10) | .58 | |||||
| Heart failure | 665 (5.25) | 249 (5.90) | 220 (5.21) | 196 (4.64) | Erlotinib | 0.93 (0.77-1.11) | .41 | 1.03 (0.86-1.24) | .72 |
| Afatinib | 0.73 (0.60-0.88) | .001 | 1.02 (0.84-1.24) | .84 | |||||
| Acute myocardial infarction | 150 (1.18) | 61 (1.44) | 49 (1.16) | 40 (0.95) | Erlotinib | 0.85 (0.58-1.24) | .39 | 0.95 (0.65-1.39) | .81 |
| Afatinib | 0.60 (0.40-0.90) | .01 | 0.81 (0.54-1.23) | .32 | |||||
| Ischemic stroke | 862 (6.81) | 310 (7.34) | 285 (6.75) | 267 (6.32) | Erlotinib | 0.97 (0.83-1.14) | .73 | 1.02 (0.86-1.19) | .86 |
| Afatinib | 0.79 (0.67-0.94) | .006 | 0.90 (0.76-1.06) | .22 | |||||
Abbreviations: HR, hazard ratio; MACCEs, major adverse cardiac and cerebrovascular events; TKIs, tyrosine kinase inhibitors.
a
Model was adjusted for age, sex, stage, therapies used during (radiotherapy, operation, antiarrhythmia drugs, anticancer drugs, platinum analogues), cardiovascular medication (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, β-blocker, anti-platelet agents, anticoagulants, statins, digoxin, mineralocorticoid-receptor antagonists), comorbidities (coronary artery disease, peripheral artery disease, hypertension, diabetes, hyperlipidemia, valve disease, chronic obstructive lung disease, asthma, chronic kidney disease, end-stage kidney disease).